| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spectroscopy, Near-Infrared | 31 | 2024 | 750 | 3.810 |
Why?
|
| Plaque, Atherosclerotic | 27 | 2024 | 1529 | 2.460 |
Why?
|
| Coronary Artery Disease | 44 | 2024 | 6544 | 2.010 |
Why?
|
| Coronary Vessels | 29 | 2024 | 3096 | 1.840 |
Why?
|
| Myocardial Infarction | 120 | 2022 | 11499 | 1.730 |
Why?
|
| Nuclear Warfare | 2 | 2020 | 30 | 1.330 |
Why?
|
| Ultrasonography, Interventional | 17 | 2024 | 1531 | 1.160 |
Why?
|
| Lipids | 17 | 2021 | 3315 | 1.150 |
Why?
|
| Circadian Rhythm | 40 | 2006 | 2592 | 1.140 |
Why?
|
| Nuclear Weapons | 1 | 2023 | 12 | 0.880 |
Why?
|
| Coronary Disease | 36 | 2020 | 5912 | 0.730 |
Why?
|
| Anger | 9 | 2016 | 402 | 0.700 |
Why?
|
| Global Warming | 1 | 2020 | 79 | 0.650 |
Why?
|
| Physical Exertion | 14 | 2015 | 665 | 0.640 |
Why?
|
| International Cooperation | 3 | 2023 | 1432 | 0.630 |
Why?
|
| Death, Sudden, Cardiac | 20 | 2020 | 1568 | 0.590 |
Why?
|
| Platelet Aggregation | 17 | 2001 | 769 | 0.570 |
Why?
|
| Professional Role | 1 | 2019 | 313 | 0.520 |
Why?
|
| Cardiovascular System | 1 | 2023 | 841 | 0.490 |
Why?
|
| Angioscopy | 6 | 2014 | 46 | 0.480 |
Why?
|
| Coronary Angiography | 19 | 2017 | 4493 | 0.450 |
Why?
|
| Multicenter Studies as Topic | 6 | 2017 | 1731 | 0.450 |
Why?
|
| Cardiovascular Diseases | 29 | 2020 | 15652 | 0.420 |
Why?
|
| Nifedipine | 15 | 1998 | 220 | 0.410 |
Why?
|
| Fibrinolysis | 7 | 2001 | 331 | 0.410 |
Why?
|
| Arteriosclerosis | 7 | 2005 | 1053 | 0.400 |
Why?
|
| Coronary Thrombosis | 10 | 2007 | 440 | 0.370 |
Why?
|
| Predictive Value of Tests | 21 | 2024 | 15398 | 0.370 |
Why?
|
| Coronary Stenosis | 4 | 2010 | 800 | 0.350 |
Why?
|
| Death, Sudden | 9 | 1997 | 300 | 0.340 |
Why?
|
| Atherosclerosis | 9 | 2020 | 3424 | 0.340 |
Why?
|
| Angioplasty, Balloon, Coronary | 8 | 2014 | 1727 | 0.320 |
Why?
|
| Aspirin | 12 | 2020 | 3134 | 0.310 |
Why?
|
| Actins | 1 | 2016 | 2056 | 0.310 |
Why?
|
| Humans | 241 | 2024 | 765968 | 0.290 |
Why?
|
| Calcium | 3 | 2018 | 5767 | 0.290 |
Why?
|
| Diagnostic Imaging | 3 | 2010 | 3529 | 0.290 |
Why?
|
| Photosensitizing Agents | 3 | 2008 | 625 | 0.290 |
Why?
|
| Rupture, Spontaneous | 6 | 2015 | 359 | 0.290 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2016 | 2570 | 0.270 |
Why?
|
| Fiber Optic Technology | 1 | 2008 | 284 | 0.270 |
Why?
|
| Angina, Unstable | 6 | 2021 | 893 | 0.270 |
Why?
|
| Bioterrorism | 4 | 2007 | 144 | 0.260 |
Why?
|
| Angina Pectoris | 15 | 2003 | 956 | 0.250 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3100 | 0.250 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3223 | 0.250 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 2900 | 0.250 |
Why?
|
| Electrocardiography | 25 | 2014 | 6404 | 0.250 |
Why?
|
| Stress, Physiological | 3 | 2006 | 1402 | 0.240 |
Why?
|
| Middle Aged | 129 | 2021 | 223009 | 0.240 |
Why?
|
| Photochemotherapy | 2 | 2008 | 826 | 0.230 |
Why?
|
| Risk Factors | 60 | 2020 | 74840 | 0.230 |
Why?
|
| Heart Arrest | 2 | 2014 | 1516 | 0.230 |
Why?
|
| Tomography, Optical Coherence | 3 | 2024 | 2932 | 0.230 |
Why?
|
| Risk | 17 | 2016 | 9591 | 0.220 |
Why?
|
| Sexual Behavior | 4 | 2006 | 2193 | 0.220 |
Why?
|
| Heart | 8 | 2023 | 4414 | 0.220 |
Why?
|
| Myocardial Ischemia | 6 | 1999 | 2128 | 0.220 |
Why?
|
| Aged | 91 | 2021 | 171117 | 0.210 |
Why?
|
| Ventricular Fibrillation | 6 | 2007 | 533 | 0.210 |
Why?
|
| Arterial Occlusive Diseases | 3 | 2006 | 729 | 0.210 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2003 | 185 | 0.210 |
Why?
|
| Catheterization | 1 | 2008 | 1425 | 0.210 |
Why?
|
| Marijuana Smoking | 2 | 2008 | 261 | 0.200 |
Why?
|
| Risk Reduction Behavior | 2 | 2020 | 1123 | 0.200 |
Why?
|
| User-Computer Interface | 1 | 2008 | 1405 | 0.190 |
Why?
|
| Male | 142 | 2021 | 363698 | 0.190 |
Why?
|
| Verapamil | 6 | 2005 | 242 | 0.190 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 6 | 2005 | 282 | 0.190 |
Why?
|
| Calcinosis | 4 | 2011 | 1479 | 0.190 |
Why?
|
| Fibrosis | 3 | 2015 | 2070 | 0.190 |
Why?
|
| Exercise | 9 | 1996 | 5937 | 0.180 |
Why?
|
| Spectrum Analysis | 1 | 2003 | 443 | 0.180 |
Why?
|
| Adrenergic beta-Antagonists | 13 | 2013 | 1237 | 0.180 |
Why?
|
| Creatine Kinase | 17 | 2011 | 682 | 0.180 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2003 | 516 | 0.170 |
Why?
|
| Necrosis | 7 | 2015 | 1617 | 0.170 |
Why?
|
| Tissue Plasminogen Activator | 8 | 2004 | 1167 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 10383 | 0.170 |
Why?
|
| Female | 125 | 2021 | 396112 | 0.170 |
Why?
|
| Prognosis | 31 | 2017 | 29922 | 0.160 |
Why?
|
| Coronary Circulation | 8 | 2005 | 1602 | 0.160 |
Why?
|
| Posture | 7 | 1999 | 954 | 0.160 |
Why?
|
| Risk Assessment | 19 | 2020 | 24282 | 0.160 |
Why?
|
| Stress, Psychological | 10 | 2012 | 4533 | 0.160 |
Why?
|
| Defibrillators, Implantable | 4 | 2007 | 1490 | 0.160 |
Why?
|
| Membrane Proteins | 1 | 2016 | 7851 | 0.160 |
Why?
|
| Fibrinogen | 8 | 2005 | 895 | 0.160 |
Why?
|
| Tachycardia, Ventricular | 6 | 2007 | 1310 | 0.160 |
Why?
|
| Acute Coronary Syndrome | 3 | 2020 | 2184 | 0.150 |
Why?
|
| Sympathetic Nervous System | 2 | 1995 | 520 | 0.150 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 10261 | 0.150 |
Why?
|
| Prospective Studies | 28 | 2021 | 54802 | 0.150 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2003 | 1145 | 0.150 |
Why?
|
| Blood Platelets | 4 | 1992 | 2464 | 0.150 |
Why?
|
| Nadolol | 3 | 1994 | 29 | 0.140 |
Why?
|
| Autopsy | 5 | 2017 | 1011 | 0.140 |
Why?
|
| Weather | 1 | 2018 | 234 | 0.140 |
Why?
|
| Thrombosis | 5 | 2010 | 2949 | 0.140 |
Why?
|
| Hypertension | 13 | 2006 | 8626 | 0.140 |
Why?
|
| Cross-Over Studies | 10 | 2012 | 2108 | 0.140 |
Why?
|
| Alcohol Drinking | 6 | 2015 | 4040 | 0.130 |
Why?
|
| Embolism | 2 | 2010 | 400 | 0.130 |
Why?
|
| Vasoconstrictor Agents | 2 | 2001 | 655 | 0.130 |
Why?
|
| Sex | 1 | 1996 | 53 | 0.130 |
Why?
|
| Nursing Homes | 2 | 2021 | 1084 | 0.130 |
Why?
|
| Coronary Artery Bypass | 7 | 2016 | 2186 | 0.130 |
Why?
|
| Stents | 6 | 2015 | 3213 | 0.130 |
Why?
|
| Anxiety | 3 | 2016 | 4671 | 0.130 |
Why?
|
| Arrhythmias, Cardiac | 7 | 2006 | 2247 | 0.130 |
Why?
|
| Carotid Stenosis | 4 | 2006 | 861 | 0.130 |
Why?
|
| Perioperative Care | 1 | 2003 | 1055 | 0.120 |
Why?
|
| ROC Curve | 3 | 2016 | 3620 | 0.120 |
Why?
|
| Policy Making | 1 | 2019 | 546 | 0.120 |
Why?
|
| Communicable Diseases, Emerging | 2 | 2007 | 150 | 0.120 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2008 | 4034 | 0.120 |
Why?
|
| Thromboxane A2 | 2 | 1992 | 87 | 0.120 |
Why?
|
| Syndrome | 4 | 2007 | 3271 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2020 | 2770 | 0.120 |
Why?
|
| Vasodilator Agents | 5 | 2003 | 988 | 0.120 |
Why?
|
| Alcoholic Beverages | 2 | 2015 | 265 | 0.120 |
Why?
|
| Tea | 3 | 2006 | 290 | 0.120 |
Why?
|
| Severity of Illness Index | 11 | 2017 | 15880 | 0.120 |
Why?
|
| Fibrinolytic Agents | 5 | 1999 | 2080 | 0.110 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2017 | 280 | 0.110 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 586 | 0.110 |
Why?
|
| Blood Pressure | 17 | 2005 | 8532 | 0.110 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 1995 | 187 | 0.110 |
Why?
|
| Aorta | 1 | 2002 | 2028 | 0.110 |
Why?
|
| Pyridines | 10 | 1983 | 2888 | 0.110 |
Why?
|
| Cocaine | 1 | 1999 | 946 | 0.110 |
Why?
|
| Educational Status | 4 | 2004 | 2513 | 0.110 |
Why?
|
| Hemostasis | 4 | 2005 | 467 | 0.110 |
Why?
|
| Drug-Eluting Stents | 1 | 2020 | 683 | 0.110 |
Why?
|
| Electric Countershock | 3 | 2007 | 534 | 0.110 |
Why?
|
| Public Health | 4 | 2007 | 2680 | 0.110 |
Why?
|
| Saphenous Vein | 1 | 2016 | 511 | 0.110 |
Why?
|
| Calcium Channel Blockers | 6 | 2003 | 686 | 0.110 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2016 | 540 | 0.100 |
Why?
|
| Time Factors | 31 | 2015 | 40065 | 0.100 |
Why?
|
| Area Under Curve | 2 | 2016 | 1638 | 0.100 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2001 | 580 | 0.100 |
Why?
|
| Primary Prevention | 1 | 2020 | 1187 | 0.100 |
Why?
|
| Estrogen Replacement Therapy | 2 | 1998 | 1206 | 0.100 |
Why?
|
| Confidence Intervals | 5 | 2015 | 2910 | 0.100 |
Why?
|
| Hemodynamics | 8 | 2007 | 4184 | 0.100 |
Why?
|
| Survivors | 3 | 2014 | 2372 | 0.100 |
Why?
|
| Embolism, Cholesterol | 1 | 2011 | 33 | 0.100 |
Why?
|
| Vascular Resistance | 4 | 1991 | 941 | 0.100 |
Why?
|
| Widowhood | 1 | 2012 | 51 | 0.090 |
Why?
|
| Hyaluronoglucosaminidase | 5 | 1984 | 138 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 3251 | 0.090 |
Why?
|
| Coffee | 2 | 2006 | 593 | 0.090 |
Why?
|
| Mass Screening | 3 | 2020 | 5446 | 0.090 |
Why?
|
| Atenolol | 2 | 2003 | 99 | 0.090 |
Why?
|
| Coronary Vasospasm | 4 | 1983 | 81 | 0.090 |
Why?
|
| Acute Disease | 9 | 2006 | 7232 | 0.090 |
Why?
|
| Double-Blind Method | 15 | 2008 | 12437 | 0.090 |
Why?
|
| Aged, 80 and over | 15 | 2018 | 59489 | 0.090 |
Why?
|
| Epinephrine | 8 | 2001 | 783 | 0.090 |
Why?
|
| Ultrasonography | 3 | 2021 | 5993 | 0.090 |
Why?
|
| Antigens, Human Platelet | 2 | 2001 | 41 | 0.090 |
Why?
|
| Adult | 58 | 2015 | 223044 | 0.080 |
Why?
|
| Clinical Trials as Topic | 13 | 1999 | 8041 | 0.080 |
Why?
|
| Grief | 1 | 2012 | 255 | 0.080 |
Why?
|
| Interviews as Topic | 4 | 2001 | 2739 | 0.080 |
Why?
|
| Cardiology | 1 | 2020 | 1702 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1999 | 2268 | 0.080 |
Why?
|
| Follow-Up Studies | 23 | 2020 | 39193 | 0.080 |
Why?
|
| Cause of Death | 4 | 2015 | 3708 | 0.080 |
Why?
|
| Survival Analysis | 9 | 2015 | 10070 | 0.080 |
Why?
|
| Diabetic Angiopathies | 2 | 2005 | 805 | 0.080 |
Why?
|
| Case-Control Studies | 7 | 2015 | 22223 | 0.080 |
Why?
|
| Angioplasty | 1 | 2011 | 352 | 0.080 |
Why?
|
| Sexual Dysfunctions, Psychological | 2 | 2000 | 193 | 0.080 |
Why?
|
| Adenosine Diphosphate | 7 | 2001 | 419 | 0.080 |
Why?
|
| Drinking Behavior | 2 | 2005 | 101 | 0.070 |
Why?
|
| Factor VII | 4 | 2004 | 139 | 0.070 |
Why?
|
| Smoking Cessation | 1 | 2020 | 2084 | 0.070 |
Why?
|
| Estrogens | 1 | 1995 | 1529 | 0.070 |
Why?
|
| Hyperlipidemias | 2 | 2006 | 770 | 0.070 |
Why?
|
| Antihypertensive Agents | 3 | 2006 | 2033 | 0.070 |
Why?
|
| Angina Pectoris, Variant | 6 | 1983 | 52 | 0.070 |
Why?
|
| Dogs | 11 | 1999 | 3822 | 0.070 |
Why?
|
| Receptors, Scavenger | 1 | 2007 | 123 | 0.070 |
Why?
|
| Incidence | 9 | 2018 | 21480 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2006 | 2024 | 0.070 |
Why?
|
| Heart Rate | 12 | 1997 | 4204 | 0.070 |
Why?
|
| Life Change Events | 1 | 2012 | 954 | 0.070 |
Why?
|
| Spironolactone | 1 | 1990 | 415 | 0.070 |
Why?
|
| Digoxin | 3 | 1986 | 246 | 0.070 |
Why?
|
| Reproducibility of Results | 7 | 2016 | 20124 | 0.070 |
Why?
|
| Inflammation | 3 | 2022 | 10850 | 0.070 |
Why?
|
| Pandemics | 3 | 2021 | 8703 | 0.070 |
Why?
|
| Emotions | 3 | 2016 | 2763 | 0.060 |
Why?
|
| United States | 21 | 2021 | 72903 | 0.060 |
Why?
|
| Sensitivity and Specificity | 6 | 2005 | 14652 | 0.060 |
Why?
|
| Recurrence | 10 | 2011 | 8501 | 0.060 |
Why?
|
| Proportional Hazards Models | 11 | 2015 | 12509 | 0.060 |
Why?
|
| Clinical Enzyme Tests | 3 | 1999 | 114 | 0.060 |
Why?
|
| Cohort Studies | 15 | 2015 | 41649 | 0.060 |
Why?
|
| Rupture | 1 | 2007 | 443 | 0.060 |
Why?
|
| Logistic Models | 4 | 2013 | 13266 | 0.060 |
Why?
|
| Arousal | 3 | 1999 | 1171 | 0.060 |
Why?
|
| Hemorrhage | 1 | 2017 | 3461 | 0.060 |
Why?
|
| Polymorphism, Genetic | 3 | 2001 | 4247 | 0.060 |
Why?
|
| Catecholamines | 2 | 1999 | 383 | 0.060 |
Why?
|
| Serum Albumin, Bovine | 1 | 2006 | 318 | 0.060 |
Why?
|
| Electrocardiography, Ambulatory | 3 | 1999 | 582 | 0.060 |
Why?
|
| Prothrombin | 1 | 2005 | 193 | 0.060 |
Why?
|
| Disease Susceptibility | 3 | 2006 | 1789 | 0.060 |
Why?
|
| Tablets, Enteric-Coated | 3 | 1997 | 21 | 0.060 |
Why?
|
| Random Allocation | 11 | 1989 | 2395 | 0.060 |
Why?
|
| Radionuclide Imaging | 4 | 2005 | 1978 | 0.060 |
Why?
|
| Thrombophilia | 2 | 2004 | 308 | 0.060 |
Why?
|
| Coitus | 2 | 2002 | 133 | 0.060 |
Why?
|
| Interview, Psychological | 3 | 2013 | 812 | 0.060 |
Why?
|
| Microvessels | 1 | 2008 | 591 | 0.060 |
Why?
|
| Sweden | 2 | 2018 | 1381 | 0.060 |
Why?
|
| Research Design | 3 | 2007 | 6209 | 0.060 |
Why?
|
| Disease Models, Animal | 5 | 2007 | 18293 | 0.060 |
Why?
|
| Porphyrins | 1 | 2006 | 351 | 0.050 |
Why?
|
| Marijuana Abuse | 1 | 2008 | 411 | 0.050 |
Why?
|
| Treatment Outcome | 12 | 2020 | 65188 | 0.050 |
Why?
|
| Heart Failure | 11 | 2004 | 11840 | 0.050 |
Why?
|
| Hydrocortisone | 3 | 1999 | 1827 | 0.050 |
Why?
|
| Stroke Volume | 9 | 2004 | 5596 | 0.050 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2005 | 314 | 0.050 |
Why?
|
| Sulfonylurea Compounds | 1 | 2005 | 221 | 0.050 |
Why?
|
| Prosthesis Design | 1 | 2010 | 2105 | 0.050 |
Why?
|
| Carotid Artery, Internal | 1 | 2006 | 437 | 0.050 |
Why?
|
| Epidemiologic Studies | 1 | 2006 | 677 | 0.050 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2003 | 77 | 0.050 |
Why?
|
| Hydrochlorothiazide | 1 | 2003 | 95 | 0.050 |
Why?
|
| Activities of Daily Living | 2 | 1989 | 2415 | 0.050 |
Why?
|
| Age Factors | 10 | 2016 | 18380 | 0.050 |
Why?
|
| Netherlands | 3 | 2012 | 2277 | 0.050 |
Why?
|
| Rabbits | 4 | 2007 | 4734 | 0.050 |
Why?
|
| Isoenzymes | 10 | 1989 | 1689 | 0.050 |
Why?
|
| Automobile Driving | 1 | 2007 | 441 | 0.050 |
Why?
|
| Diabetes Complications | 4 | 2001 | 1316 | 0.050 |
Why?
|
| Animals | 24 | 2024 | 168764 | 0.050 |
Why?
|
| Hypolipidemic Agents | 1 | 2006 | 608 | 0.050 |
Why?
|
| Chi-Square Distribution | 3 | 2016 | 3432 | 0.050 |
Why?
|
| Radiology, Interventional | 1 | 2006 | 485 | 0.050 |
Why?
|
| Algorithms | 5 | 2020 | 14071 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2004 | 2263 | 0.050 |
Why?
|
| Vasodilation | 2 | 2005 | 970 | 0.050 |
Why?
|
| Personality Inventory | 2 | 2013 | 1018 | 0.050 |
Why?
|
| Beverages | 1 | 2006 | 819 | 0.050 |
Why?
|
| Feasibility Studies | 4 | 2009 | 5302 | 0.050 |
Why?
|
| Vasculitis | 1 | 2005 | 527 | 0.040 |
Why?
|
| Equipment Design | 2 | 2024 | 3481 | 0.040 |
Why?
|
| Life Style | 2 | 2006 | 3926 | 0.040 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2002 | 252 | 0.040 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2002 | 697 | 0.040 |
Why?
|
| Propranolol | 5 | 1989 | 492 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2006 | 1003 | 0.040 |
Why?
|
| Terminology as Topic | 2 | 2004 | 1534 | 0.040 |
Why?
|
| Multivariate Analysis | 4 | 2016 | 12056 | 0.040 |
Why?
|
| Reference Values | 4 | 1999 | 4908 | 0.040 |
Why?
|
| Thrombolytic Therapy | 4 | 2002 | 2059 | 0.040 |
Why?
|
| Diffusion of Innovation | 1 | 2024 | 721 | 0.040 |
Why?
|
| Caffeine | 1 | 2004 | 702 | 0.040 |
Why?
|
| Analysis of Variance | 6 | 2006 | 6203 | 0.040 |
Why?
|
| Terrorism | 1 | 2002 | 211 | 0.040 |
Why?
|
| Respiratory Tract Infections | 1 | 2006 | 1008 | 0.040 |
Why?
|
| Odds Ratio | 5 | 2006 | 9649 | 0.040 |
Why?
|
| Menstrual Cycle | 1 | 2002 | 540 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2002 | 951 | 0.040 |
Why?
|
| Prostaglandins | 1 | 1999 | 396 | 0.040 |
Why?
|
| Biology | 1 | 2020 | 293 | 0.040 |
Why?
|
| Folic Acid | 1 | 2005 | 1338 | 0.040 |
Why?
|
| Blood Viscosity | 3 | 2005 | 125 | 0.040 |
Why?
|
| Sex Factors | 9 | 2015 | 10603 | 0.040 |
Why?
|
| Platelet Activation | 2 | 1999 | 645 | 0.040 |
Why?
|
| Nitroglycerin | 5 | 1983 | 331 | 0.040 |
Why?
|
| Postmenopause | 2 | 1998 | 2515 | 0.040 |
Why?
|
| von Willebrand Factor | 4 | 2005 | 676 | 0.040 |
Why?
|
| Time | 2 | 1991 | 550 | 0.040 |
Why?
|
| Age Distribution | 1 | 2003 | 2858 | 0.040 |
Why?
|
| Myocardial Contraction | 4 | 1983 | 1515 | 0.040 |
Why?
|
| Hypobetalipoproteinemias | 1 | 1997 | 11 | 0.030 |
Why?
|
| Radiopharmaceuticals | 2 | 2005 | 2699 | 0.030 |
Why?
|
| Patient Care | 1 | 2022 | 629 | 0.030 |
Why?
|
| Massachusetts | 4 | 2001 | 8875 | 0.030 |
Why?
|
| Patient Selection | 2 | 2012 | 4255 | 0.030 |
Why?
|
| Heparin | 1 | 1984 | 1630 | 0.030 |
Why?
|
| Shock, Cardiogenic | 3 | 1989 | 704 | 0.030 |
Why?
|
| Death | 1 | 2021 | 686 | 0.030 |
Why?
|
| Europe | 1 | 2003 | 3423 | 0.030 |
Why?
|
| Norepinephrine | 3 | 1994 | 900 | 0.030 |
Why?
|
| Linear Models | 2 | 2012 | 5876 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2008 | 3356 | 0.030 |
Why?
|
| Tachycardia | 3 | 1987 | 594 | 0.030 |
Why?
|
| Positron-Emission Tomography | 3 | 2006 | 6547 | 0.030 |
Why?
|
| Chest Pain | 1 | 2002 | 1100 | 0.030 |
Why?
|
| Viper Venoms | 1 | 1995 | 15 | 0.030 |
Why?
|
| Heart Diseases | 2 | 1996 | 2821 | 0.030 |
Why?
|
| Body Height | 1 | 2001 | 1562 | 0.030 |
Why?
|
| Texas | 1 | 2016 | 410 | 0.030 |
Why?
|
| Enzyme Precursors | 1 | 1995 | 164 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 1997 | 384 | 0.030 |
Why?
|
| Michigan | 1 | 2016 | 328 | 0.030 |
Why?
|
| Physician's Role | 1 | 2002 | 927 | 0.030 |
Why?
|
| Autonomic Nervous System | 2 | 1997 | 706 | 0.030 |
Why?
|
| Embolic Protection Devices | 1 | 2015 | 43 | 0.030 |
Why?
|
| Cross-Sectional Studies | 5 | 2021 | 26318 | 0.030 |
Why?
|
| Myocardium | 10 | 2003 | 4760 | 0.030 |
Why?
|
| Causality | 1 | 2001 | 1248 | 0.030 |
Why?
|
| Suicide, Attempted | 1 | 2004 | 1409 | 0.030 |
Why?
|
| Dreams | 1 | 1996 | 144 | 0.030 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2015 | 202 | 0.030 |
Why?
|
| Public Health Administration | 2 | 2007 | 241 | 0.030 |
Why?
|
| Cholesterol, Dietary | 1 | 1995 | 223 | 0.030 |
Why?
|
| Prevalence | 4 | 2006 | 15842 | 0.030 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 1995 | 323 | 0.030 |
Why?
|
| Macrophages | 2 | 2006 | 5772 | 0.030 |
Why?
|
| Diuretics | 2 | 2003 | 613 | 0.030 |
Why?
|
| Emergencies | 1 | 1980 | 1223 | 0.030 |
Why?
|
| Forecasting | 2 | 2020 | 2936 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2006 | 36532 | 0.030 |
Why?
|
| Sleep Stages | 1 | 1997 | 698 | 0.030 |
Why?
|
| Registries | 3 | 2020 | 8297 | 0.030 |
Why?
|
| Rage | 1 | 2013 | 29 | 0.030 |
Why?
|
| Vasoconstriction | 3 | 1981 | 594 | 0.030 |
Why?
|
| Platelet Count | 3 | 1999 | 782 | 0.030 |
Why?
|
| Mental Processes | 1 | 1994 | 243 | 0.030 |
Why?
|
| Data Collection | 1 | 2002 | 3318 | 0.030 |
Why?
|
| Obesity | 3 | 2004 | 13076 | 0.030 |
Why?
|
| Diagnosis, Differential | 3 | 2016 | 12976 | 0.030 |
Why?
|
| Histamine | 1 | 1995 | 497 | 0.030 |
Why?
|
| Lipectomy | 1 | 2014 | 114 | 0.030 |
Why?
|
| Exercise Test | 5 | 1999 | 2180 | 0.030 |
Why?
|
| Insulin | 4 | 2005 | 6599 | 0.030 |
Why?
|
| Comorbidity | 3 | 2004 | 10563 | 0.030 |
Why?
|
| Advisory Committees | 2 | 2007 | 796 | 0.030 |
Why?
|
| Diabetes Mellitus | 5 | 2004 | 5891 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2002 | 3672 | 0.030 |
Why?
|
| Galvanic Skin Response | 1 | 1994 | 359 | 0.030 |
Why?
|
| Demography | 3 | 2004 | 1641 | 0.030 |
Why?
|
| Sleep, REM | 1 | 1996 | 588 | 0.030 |
Why?
|
| Retrospective Studies | 11 | 2020 | 81514 | 0.020 |
Why?
|
| Statistics, Nonparametric | 3 | 2006 | 2844 | 0.020 |
Why?
|
| Survival Rate | 4 | 2014 | 12795 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 2005 | 3714 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 2 | 1989 | 1470 | 0.020 |
Why?
|
| Streptokinase | 2 | 1983 | 185 | 0.020 |
Why?
|
| Receptors, Adrenergic | 1 | 1992 | 155 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2015 | 8733 | 0.020 |
Why?
|
| Sleep | 3 | 1997 | 4813 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 1892 | 0.020 |
Why?
|
| Tissue Distribution | 2 | 2006 | 2266 | 0.020 |
Why?
|
| Propanolamines | 1 | 1992 | 163 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 1996 | 1326 | 0.020 |
Why?
|
| Fluorescein Angiography | 1 | 2017 | 1085 | 0.020 |
Why?
|
| Estradiol | 1 | 1998 | 1947 | 0.020 |
Why?
|
| Delayed-Action Preparations | 3 | 2003 | 967 | 0.020 |
Why?
|
| Epoprostenol | 1 | 1992 | 246 | 0.020 |
Why?
|
| Premenopause | 1 | 1995 | 1037 | 0.020 |
Why?
|
| Nuclear Family | 1 | 2012 | 311 | 0.020 |
Why?
|
| Organ Specificity | 2 | 2006 | 1965 | 0.020 |
Why?
|
| Ventricular Function, Left | 2 | 1995 | 3928 | 0.020 |
Why?
|
| Fear | 1 | 1999 | 1499 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2004 | 6832 | 0.020 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2020 | 1211 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2016 | 2352 | 0.020 |
Why?
|
| Carbazoles | 1 | 1992 | 229 | 0.020 |
Why?
|
| No-Reflow Phenomenon | 1 | 2009 | 16 | 0.020 |
Why?
|
| Thrombectomy | 1 | 2014 | 681 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2004 | 13039 | 0.020 |
Why?
|
| Heart Rupture | 1 | 1989 | 21 | 0.020 |
Why?
|
| Postoperative Complications | 2 | 2011 | 15747 | 0.020 |
Why?
|
| Electrolytes | 1 | 1990 | 280 | 0.020 |
Why?
|
| Heart Rupture, Post-Infarction | 1 | 1989 | 48 | 0.020 |
Why?
|
| Hematocrit | 2 | 1988 | 621 | 0.020 |
Why?
|
| Hospitalization | 9 | 2013 | 10808 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 1996 | 937 | 0.020 |
Why?
|
| Metoprolol | 1 | 1989 | 89 | 0.020 |
Why?
|
| Drug Therapy, Combination | 3 | 1990 | 6309 | 0.020 |
Why?
|
| Smoking | 6 | 2004 | 9081 | 0.020 |
Why?
|
| Kidney Tubules | 1 | 1990 | 453 | 0.020 |
Why?
|
| Actuarial Analysis | 2 | 2004 | 366 | 0.020 |
Why?
|
| Myocardial Revascularization | 1 | 2012 | 793 | 0.020 |
Why?
|
| Wakefulness | 1 | 1995 | 1282 | 0.020 |
Why?
|
| History, 19th Century | 2 | 1983 | 711 | 0.020 |
Why?
|
| Placebos | 3 | 1996 | 1659 | 0.020 |
Why?
|
| Regional Blood Flow | 4 | 2005 | 1478 | 0.020 |
Why?
|
| Oxygen Consumption | 4 | 1983 | 1870 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 1998 | 2136 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2001 | 791 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2011 | 20659 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 1997 | 2393 | 0.020 |
Why?
|
| Air Pollution | 1 | 2001 | 2380 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 1991 | 1589 | 0.020 |
Why?
|
| Pericarditis | 1 | 1989 | 137 | 0.020 |
Why?
|
| Troponin I | 1 | 2011 | 655 | 0.020 |
Why?
|
| Fluorocarbons | 2 | 1983 | 497 | 0.020 |
Why?
|
| Stroke | 2 | 2006 | 9747 | 0.020 |
Why?
|
| Aging | 1 | 2005 | 8731 | 0.020 |
Why?
|
| Bundle-Branch Block | 1 | 1988 | 280 | 0.020 |
Why?
|
| Chlorophyllides | 1 | 2006 | 54 | 0.020 |
Why?
|
| Ticlopidine | 1 | 2010 | 731 | 0.020 |
Why?
|
| Tissue Polypeptide Antigen | 1 | 2005 | 4 | 0.020 |
Why?
|
| Injections, Intravenous | 3 | 1983 | 1377 | 0.020 |
Why?
|
| Death Certificates | 1 | 1987 | 170 | 0.020 |
Why?
|
| Cholesterol | 1 | 1995 | 2898 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 1999 | 3000 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2006 | 360 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 3236 | 0.020 |
Why?
|
| Age of Onset | 2 | 2003 | 3344 | 0.020 |
Why?
|
| Centrifugation | 1 | 2005 | 121 | 0.020 |
Why?
|
| Research | 1 | 1994 | 1975 | 0.020 |
Why?
|
| Swine | 2 | 2007 | 5988 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2016 | 2737 | 0.020 |
Why?
|
| Nitrates | 2 | 1984 | 260 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2002 | 4416 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2005 | 284 | 0.020 |
Why?
|
| Women | 1 | 1987 | 226 | 0.020 |
Why?
|
| Schizophrenia | 1 | 2004 | 6972 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2009 | 1831 | 0.010 |
Why?
|
| Cold Temperature | 3 | 1983 | 794 | 0.010 |
Why?
|
| Heart Block | 1 | 1986 | 391 | 0.010 |
Why?
|
| Patient Compliance | 2 | 2005 | 2692 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 1991 | 1820 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2006 | 10729 | 0.010 |
Why?
|
| Diltiazem | 2 | 1980 | 132 | 0.010 |
Why?
|
| Eating | 1 | 1990 | 1540 | 0.010 |
Why?
|
| Medicare | 1 | 2021 | 6823 | 0.010 |
Why?
|
| Sleep Deprivation | 1 | 1990 | 845 | 0.010 |
Why?
|
| Psychometrics | 1 | 2013 | 3062 | 0.010 |
Why?
|
| Colorimetry | 1 | 2004 | 148 | 0.010 |
Why?
|
| Motor Activity | 1 | 2013 | 2704 | 0.010 |
Why?
|
| Carbonated Beverages | 1 | 2004 | 209 | 0.010 |
Why?
|
| Emergency Medical Services | 2 | 2002 | 1938 | 0.010 |
Why?
|
| Waist-Hip Ratio | 1 | 2004 | 520 | 0.010 |
Why?
|
| History, 20th Century | 2 | 1983 | 2761 | 0.010 |
Why?
|
| Diastole | 2 | 1998 | 785 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 3 | 1988 | 1600 | 0.010 |
Why?
|
| Philosophy, Medical | 1 | 2002 | 78 | 0.010 |
Why?
|
| Follicular Phase | 1 | 2002 | 143 | 0.010 |
Why?
|
| Markov Chains | 1 | 2005 | 968 | 0.010 |
Why?
|
| Health Care Costs | 1 | 1995 | 3242 | 0.010 |
Why?
|
| Nuclear Medicine | 1 | 2005 | 261 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2007 | 1966 | 0.010 |
Why?
|
| Heart Function Tests | 2 | 1996 | 317 | 0.010 |
Why?
|
| Africa | 1 | 2004 | 725 | 0.010 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 1983 | 220 | 0.010 |
Why?
|
| Perhexiline | 1 | 1980 | 5 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2005 | 1381 | 0.010 |
Why?
|
| Regression Analysis | 2 | 1992 | 6322 | 0.010 |
Why?
|
| Integrin beta3 | 1 | 2001 | 120 | 0.010 |
Why?
|
| Family | 1 | 2012 | 3209 | 0.010 |
Why?
|
| Oxygen | 2 | 1983 | 4241 | 0.010 |
Why?
|
| Cattle | 2 | 2004 | 3801 | 0.010 |
Why?
|
| Cardiac Output | 1 | 1983 | 840 | 0.010 |
Why?
|
| False Negative Reactions | 3 | 1988 | 573 | 0.010 |
Why?
|
| Embolization, Therapeutic | 1 | 2010 | 1403 | 0.010 |
Why?
|
| Disease Progression | 2 | 2010 | 13632 | 0.010 |
Why?
|
| Adenosine | 1 | 2005 | 806 | 0.010 |
Why?
|
| Drug Administration Schedule | 2 | 1998 | 4850 | 0.010 |
Why?
|
| Cardiotonic Agents | 1 | 1983 | 538 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2006 | 2077 | 0.010 |
Why?
|
| False Positive Reactions | 3 | 1988 | 955 | 0.010 |
Why?
|
| Family Health | 1 | 2004 | 1253 | 0.010 |
Why?
|
| Congresses as Topic | 1 | 2004 | 811 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2007 | 2394 | 0.010 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2005 | 1737 | 0.010 |
Why?
|
| Benzazepines | 1 | 1980 | 308 | 0.010 |
Why?
|
| Medical Records | 1 | 2004 | 1409 | 0.010 |
Why?
|
| Potassium | 1 | 1983 | 1311 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1978 | 303 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 3807 | 0.010 |
Why?
|
| Models, Cardiovascular | 1 | 2003 | 978 | 0.010 |
Why?
|
| USSR | 1 | 1977 | 19 | 0.010 |
Why?
|
| Heart Aneurysm | 1 | 1978 | 115 | 0.010 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 1997 | 80 | 0.010 |
Why?
|
| Carotid Arteries | 1 | 2002 | 929 | 0.010 |
Why?
|
| Cardiovascular Agents | 1 | 2004 | 851 | 0.010 |
Why?
|
| Carbon | 1 | 2001 | 677 | 0.010 |
Why?
|
| Hyaluronic Acid | 1 | 1981 | 484 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2012 | 5089 | 0.010 |
Why?
|
| Particle Size | 1 | 2001 | 1631 | 0.010 |
Why?
|
| Heart Ventricles | 5 | 1989 | 3832 | 0.010 |
Why?
|
| Longitudinal Studies | 2 | 1997 | 14751 | 0.010 |
Why?
|
| Long QT Syndrome | 1 | 2001 | 474 | 0.010 |
Why?
|
| Homozygote | 1 | 2001 | 1775 | 0.010 |
Why?
|
| Progestins | 1 | 1998 | 300 | 0.010 |
Why?
|
| Systole | 1 | 1998 | 935 | 0.010 |
Why?
|
| Fourier Analysis | 1 | 1997 | 434 | 0.010 |
Why?
|
| Genotype | 2 | 2001 | 13024 | 0.010 |
Why?
|
| Cardiopulmonary Bypass | 2 | 1978 | 1090 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2001 | 2341 | 0.010 |
Why?
|
| Heart Arrest, Induced | 1 | 1977 | 358 | 0.010 |
Why?
|
| Monitoring, Physiologic | 2 | 1997 | 1792 | 0.010 |
Why?
|
| Ion Channels | 1 | 1980 | 1045 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 2 | 2005 | 5526 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 13451 | 0.010 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2005 | 1434 | 0.010 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2002 | 1426 | 0.010 |
Why?
|
| Image Enhancement | 1 | 2006 | 2858 | 0.010 |
Why?
|
| Seasons | 1 | 2001 | 1524 | 0.010 |
Why?
|
| Isoproterenol | 1 | 1975 | 398 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2005 | 6014 | 0.010 |
Why?
|
| Epitopes | 1 | 2001 | 2523 | 0.010 |
Why?
|
| Thorax | 1 | 1978 | 554 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2006 | 2207 | 0.010 |
Why?
|
| Mortality | 1 | 2005 | 2904 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2001 | 3624 | 0.010 |
Why?
|
| Action Potentials | 2 | 1980 | 1838 | 0.010 |
Why?
|
| Glycolysis | 1 | 1978 | 838 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 11022 | 0.010 |
Why?
|
| Consensus | 1 | 2003 | 3202 | 0.010 |
Why?
|
| Polymers | 1 | 1981 | 1621 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1984 | 3715 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2004 | 2590 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1983 | 1808 | 0.010 |
Why?
|
| Phenotype | 2 | 2001 | 16721 | 0.010 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1978 | 624 | 0.010 |
Why?
|
| Heart Valve Diseases | 1 | 2000 | 1030 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2005 | 3110 | 0.010 |
Why?
|
| Yohimbine | 1 | 1992 | 62 | 0.010 |
Why?
|
| Hypothermia, Induced | 1 | 1977 | 752 | 0.010 |
Why?
|
| Vascular Patency | 1 | 1995 | 912 | 0.010 |
Why?
|
| Piperidines | 1 | 1980 | 1664 | 0.010 |
Why?
|
| Glucose | 1 | 1983 | 4335 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1992 | 1140 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 1997 | 1811 | 0.010 |
Why?
|
| Probability | 2 | 1987 | 2475 | 0.010 |
Why?
|
| Alleles | 1 | 2001 | 6897 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2001 | 18071 | 0.010 |
Why?
|
| Triglycerides | 1 | 1997 | 2441 | 0.000 |
Why?
|
| Adolescent | 4 | 2004 | 88835 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 13400 | 0.000 |
Why?
|
| Genetic Testing | 1 | 2001 | 3595 | 0.000 |
Why?
|
| Heart Septum | 1 | 1989 | 303 | 0.000 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 7425 | 0.000 |
Why?
|
| Collagen | 1 | 1996 | 2618 | 0.000 |
Why?
|
| Models, Biological | 1 | 2004 | 9443 | 0.000 |
Why?
|
| Anticoagulants | 1 | 1983 | 4862 | 0.000 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2004 | 8923 | 0.000 |
Why?
|
| Mutation | 2 | 2001 | 30198 | 0.000 |
Why?
|
| Rats | 2 | 1983 | 23707 | 0.000 |
Why?
|
| Renin | 1 | 1988 | 647 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 6493 | 0.000 |
Why?
|
| Angiotensin II | 1 | 1988 | 844 | 0.000 |
Why?
|
| Diphosphates | 1 | 1985 | 91 | 0.000 |
Why?
|
| Bradycardia | 1 | 1986 | 302 | 0.000 |
Why?
|
| Mathematics | 1 | 1985 | 696 | 0.000 |
Why?
|
| Sodium Pertechnetate Tc 99m | 1 | 1983 | 51 | 0.000 |
Why?
|
| Technetium | 1 | 1983 | 326 | 0.000 |
Why?
|
| Methods | 1 | 1983 | 1052 | 0.000 |
Why?
|
| Ambulatory Care | 1 | 1994 | 2778 | 0.000 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1986 | 769 | 0.000 |
Why?
|
| Phentolamine | 1 | 1981 | 102 | 0.000 |
Why?
|
| Blood Gas Analysis | 1 | 1982 | 380 | 0.000 |
Why?
|
| Pressoreceptors | 1 | 1981 | 98 | 0.000 |
Why?
|
| Hypotension | 1 | 1986 | 885 | 0.000 |
Why?
|
| Nitrogen | 1 | 1980 | 346 | 0.000 |
Why?
|
| Spasm | 1 | 1979 | 131 | 0.000 |
Why?
|
| Guinea Pigs | 1 | 1980 | 1300 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1981 | 2163 | 0.000 |
Why?
|
| Kidney Diseases | 1 | 1988 | 2098 | 0.000 |
Why?
|
| Electrophysiology | 1 | 1980 | 1263 | 0.000 |
Why?
|
| Biological Transport | 1 | 1982 | 2081 | 0.000 |
Why?
|
| Testis | 1 | 1981 | 780 | 0.000 |
Why?
|
| Injections, Intradermal | 1 | 1977 | 116 | 0.000 |
Why?
|
| Cyclic AMP | 1 | 1980 | 1467 | 0.000 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1977 | 412 | 0.000 |
Why?
|
| Aspartate Aminotransferases | 1 | 1977 | 415 | 0.000 |
Why?
|
| Child | 1 | 2004 | 80564 | 0.000 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 1979 | 881 | 0.000 |
Why?
|
| Sodium | 1 | 1980 | 1591 | 0.000 |
Why?
|
| Heart Conduction System | 1 | 1980 | 1006 | 0.000 |
Why?
|
| Adenosine Triphosphate | 1 | 1980 | 1999 | 0.000 |
Why?
|
| Hot Temperature | 1 | 1981 | 1433 | 0.000 |
Why?
|
| Infant | 1 | 1996 | 36386 | 0.000 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1976 | 1333 | 0.000 |
Why?
|